Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 E928A |
| Therapy | Capecitabine + Trastuzumab |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 E928A | triple-receptor negative breast cancer | predicted - sensitive | Capecitabine + Trastuzumab | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Herceptin (trastuzumab) and Xeloda (capecitabine) resulted in a partial response and reduction in circulating tumor markers, with clinical benefit ongoing after 10 months, in a triple-receptor negative breast cancer patient harboring ERBB3 (HER2) E928A who had previously progressed on several lines of therapy (PMID: 34250408). | 34250408 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34250408) | Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. | Full reference... |